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Summary 1 
The presence of hypoxia and regulatory T cells (Tregs) in tumours are both known to be 2 
negative prognostic factors in cancer, and this study demonstrated a correlation between the 3 
two factors in canine neoplasia. Samples of 57 canine tumours and 29 canine lymph nodes 4 
categorised as metastatic, draining or reactive were obtained. Sequential sections were 5 
labelled by immunohistochemistry for glucose transporter 1 (Glut1) and FoxP3 as markers of 6 
hypoxia and Tregs respectively. Up to 21 regions of interest were selected on each sample in 7 
a representative pattern and given a semi-quantitative score based on its Glut1 labelling, and 8 
the number of FoxP3+ cells at each ROI was counted. A generalised estimating equation with 9 
negative binomial log link function was used to determine an association between Glut1 10 
expression and FoxP3+ cell count. Higher Glut1 immunoreactivity was correlated with 11 
significantly higher numbers of FoxP3+ cells in the total tumour sample pool and total lymph 12 
node sample pool. Analysis on various sub-categories of tumours and lymph nodes showed 13 
this correlation was also present within samples characterised as malignant, round cell 14 
tumours, mesenchymal tumours, epithelial tumours, lymphoma, metastatic lymph nodes and 15 
reactive lymph nodes. These results indicate that hypoxia in canine tumours may result in an 16 
increased infiltration by Tregs. 17 
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Introduction 20 
Hypoxia, defined as a cellular oxygen tension below which biological functions are 21 
compromised, is a hallmark of solid tumours (Höckel and Vaupel 2001, Pinheiro et al 2014). 22 
Regions of hypoxia arise as a result of the unorganised and ineffective vasculature within 23 
tumours and their high metabolic demands (Brown and Giaccia 1998, Fenton et al 1999, 24 
Freyer 1994, Konerding et al 1995, Secomb et al 1995). Hypoxia can promote malignant 25 
changes within a tumour by activating cellular survival responses, suppression of DNA 26 
repair, and providing a selection pressure in favour of more malignant clones (Brizel et al 27 
1996, Hansen et al 2011, Höckel et al 1996, Kinoshita et al 2001, Luoto et al 2013, 28 
Pennacchietti et al 2003). Regions of hypoxia in tumours are widely accepted as a negative 29 
prognostic indicator and can result in resistance to radiotherapy and some forms of 30 
chemotherapy (Brown 2007, Comerford et al 2002, Grau and Overgaard 1992, Gray et al 31 
1953, Koch et al 2003, Snyder 2008, Vaupel and Mayer 2007, Yan et al 2011). Hypoxia is 32 
also a common finding in inflammation, as cellular metabolic requirements are also increased 33 
in this context, and oxygen supply is disrupted by alteration of local tissue structure 34 
(Eltzschig and Carmeliet 2011, Mantovani et al 2008). Hypoxia has effects on the activity 35 
and survival of several immune cells whose ability to adapt to hypoxia is crucial for an 36 
effective immune response (Imtiyaz and Simon 2010, Scholz and Taylor 2013). 37 
The response of cells to hypoxia is mediated by hypoxia inducible factor (HIF) molecules 38 
supressing or promoting the transcription of certain genes (Hansen et al 2011, Kallio et al 39 
1999, Snyder et al 2008). These HIF-induced transcriptomic changes adapt the cell to the 40 
hypoxic environment, and some of the up-regulated proteins such as glucose transporter 1 41 
(Glut1) and carbonic anhydrase IX have been shown to be biomarkers of hypoxia in certain 42 
tumours (Abbondati et al 2013, Airley et al 2003, Bussink et al 2003). 43 
Regulatory T cells (Tregs) have long been a subject of interest in oncology. In the healthy 44 
animal their function is to prevent inappropriate immune responses, and their absence or lack 45 
of function may result in autoimmune disease (Brusko et al 2008). They carry out this 46 
function by suppressing other immune cells through the production of immunosuppressive 47 
cytokines such as interleukin-10 and through cell-cell contact (Campbell and Koch 2011, 48 
Josefowicz et al 2012, Thornton and Shevach 1998). However, this immunosuppressive 49 
function can be to the body’s detriment as Tregs are thought to be a mechanism by which 50 
tumours are able to suppress the body’s anti-neoplastic immune response (Clarke et al 2006, 51 
Nishikawa and Sakaguchi 2010). To this end, high numbers of Tregs are found in a variety of 52 
different tumours and their draining lymph nodes, and in many cases higher frequencies 53 
correlate with poorer prognosis in man, rodent and dog (Deng et al 2010, Kim et al 2012, 54 
Liyanage et al 2006, Nishikawa and Sakaguchi 2010, Oh et al 2014, Pinheiro et al 2014). The 55 
principal marker for Tregs is the transcription factor Forkhead box P3 (FoxP3), which is 56 
crucial for Treg function and mutations in which result in severe autoimmune disease (Coffer 57 
and Burgering 2004). 58 
While hypoxia and Tregs have each been shown to contribute individually to a poorer 59 
clinical outcome in cancer, their effects are likely to be complementary to each other. Tregs 60 
proliferate faster under hypoxic conditions in vitro and in vivo (Clambey et al 2012, Neildez-61 
Nguyen et al 2015) and HIF1α induction increases their suppressive function in humans and 62 
mice (Ben-Shoshan et al 2008, Noman et al 2015). Tregs and hypoxia are positively 63 
correlated in a variety human tumours (Deng et al 2013, Duechler et al 2014, Facciabene et al 64 
2011, Noman et al 2015, Yan et al 2011). All of these observations suggest a link between the 65 
two factors in promoting tumour survival, but as far as the authors are aware no such 66 
association has previously been demonstrated in dogs. 67 
The purpose of this study was to further explore the link between Tregs and hypoxia 68 
within the context of canine tumours and lymph nodes. The molecules Glut1 and FoxP3 were 69 
used as biomarkers for hypoxia and Tregs respectively to investigate the hypothesis that 70 
Tregs are more abundant in areas of tumours and lymph nodes displaying high Glut1 71 
expression as a marker of hypoxia. 72 
 73 
 74 
Materials and Methods 75 
Samples 76 
The study included formalin-fixed and paraffin-embedded biopsy and necropsy samples of 77 
57 tumours and 29 lymph nodes from the archives of the Royal Veterinary College 78 
Diagnostic Laboratory, all collected by licensed veterinarians for diagnostic purposes under 79 
the Veterinary Surgeons Act (1966) following written informed consent by the owners of the 80 
dogs. Benign and malignant tumour samples were as follows: 21 samples of epithelial cell 81 
origin [adenocarcinoma (n=2), anal sac adenocarcinoma (n=1), apocrine gland carcinoma 82 
(n=1), colonic papilloma (n=1), cutaneous papilloma (n=6), cystic trichoepithelioma (n=1), 83 
mammary adenocarcinoma (n=1), mammary adenoma (n=1), meibomian gland epithelioma 84 
(n=1), squamous cell carcinoma (n=6)], 14 samples of mesenchymal cell origin 85 
[fibrosarcoma (n=4), haemangioma (n=4), haemangiosarcoma (n=2), myopericytoma (n=1), 86 
soft tissue sarcoma (n=3)], and 22 samples of round cell origin [histiocytoma (n=13), 87 
lymphoma (n=5), mast cell tumour (n=4)]. The lymph node samples were categorised as 88 
being metastatic, i.e. containing neoplastic cells (MLNs; n=10), tumour draining, i.e. sampled 89 
alongside a confirmed neoplasm in their drainage area (TDLNs; n=7), and reactive, i.e. 90 
draining sites of inflammation without neoplasia (RLNs; n=12). Sequential sections were 91 
taken from each sample. 92 
 93 
Immunohistochemistry (IHC) 94 
Slides were incubated for 20 minutes at 55˚C to melt the wax, before deparaffinisation by 95 
immersion in Neoclear® for two 5 minute changes while still molten. The slides were then 96 
hydrated by immersion in two 1 minute changes of 100% ethanol, then for 1 minute in 90% 97 
ethanol and 70% ethanol, before being placed into distilled water. 98 
Antigen retrieval was conducted by immersing slides in a solution of 10mM citrate-99 
buffered saline at pH 6 with 0.05% v/v Tween®-20 while heating in an autoclave to 126°C for 100 
25 minutes. Slides were maintained at this temperature for five minutes for Glut1 and three 101 
minutes for FoxP3. 102 
The slides were then immersed in a solution of 94% methanol and 6% hydrogen peroxide 103 
for 20 minutes to block endogenous peroxidases in the tissues; tap water was then slowly run 104 
into this solution for 5 minutes. Slides were rinsed with distilled water and then with PBS 105 
with 0.05% Tween®-20 (PBST). The tissues on the slides were covered with 10% normal 106 
goat serum (Vector Laboratories, S-1000) in PBST and incubated for 30 minutes at room 107 
temperature in a humid atmosphere. This blocking solution was replaced with stock antibody 108 
diluted in the serum blocking solution, or with the relevant isotype controls or no-primary 109 
controls incubated with only serum blocking solution (Supplementary Table 1). The slides 110 
were incubated overnight at 4˚C in a humid atmosphere. 111 
The slides were rinsed in distilled water and PBST, then covered with appropriate 112 
secondary antibody (Supplementary Table 1) and incubated for 30 minutes at room 113 
temperature in a humid atmosphere, before rinsing again in distilled water and PBST. Tissues 114 
were then covered with DAB+ Substrate Chromogen Solution® (Dako K3467) for 5 minutes 115 
at room temperature and then rinsed in distilled water and PBST. Tissues were then covered 116 
with haematoxylin for 30 seconds to counterstain, then rinsed with distilled water. Samples 117 
were dehydrated by immersing for 30 seconds in 70% ethanol, 30 seconds in 90% ethanol, 118 
two 2 minute changes and a 3 minute change of 100% ethanol then three 5 minute changes of 119 
xylene. The samples were then mounted with DPX (Fisher, 12658646). 120 
Image analysis 121 
Each slide was visually inspected for antibody labelling, and an image was taken at 122 
regions of interest (ROIs) on each Glut1-labelled slide at a 20X magnification using a Leica 123 
DFC300 FX camera (Leica Microsystems UK LTD). Another image was taken at the 124 
corresponding sites on the FoxP3-labelled slide. Up to 21 ROI were selected within each 125 
sample following a standardized, radial pattern (Supplemental Figure 1) in order to be 126 
representative of the whole section, with size and shape differences necessitating variation of 127 
the pattern in some samples. 128 
Each ROI was categorised for its Glut expression using an established method (Abbondati  129 
et al 2013, Petty et al 2008). Images of the Glut1-labelled slides were first given a score 130 
based on the estimated proportion of cells showing positive Glut1 expression, with <1% 131 
given a score of 0, 2-50% given a score of 1, and 51-100% given a score of 2. A macro was 132 
then developed using Volocity® software (PerkinElmer Inc, Massachusetts) to highlight areas 133 
that had an intensity of labelling above a threshold we had arbitrarily designated as “strong”. 134 
The criteria for this designation were: hue from 201 to 37, saturation above 80 and intensity 135 
above 14. Areas smaller than 10 pixels were discarded as noise. ROIs were given an intensity 136 
score of 1 or 2 predicated on whether this strong expression was estimated to be present in 137 
less than or greater than 50% of the labelled cells respectively. Both of these measurements 138 
were made by a single observer, and the product of these two scores was then taken to give 139 
the ROI a final Glut1 immuno-reactivity score of either 0, 1, 2 or 4. Examples of these scores 140 
are given in Supplemental Figures 2-6. 141 
The numbers of FoxP3+ cells present within each ROI were then quantified. Each image 142 
was first assessed for regions of exclusion, defined as areas of vasculature, dead space and 143 
folded tissue due to antigen retrieval.  If regions of exclusion were present they were covered 144 
over in green using Paint.NET software (Figure 6) and their area measured using Volocity®. 145 
The images were then considered for presence of endogenous pigments including melanin, 146 
haemosiderin and lipofuscin. If these pigments constituted <1% area of the ROI a macro 147 
developed in Volocity® was applied to determine the Treg count, an example of which is 148 
given in Figure 6. If these pigments constituted >1% area of an ROI, Tregs were manually 149 
counted with the help of the counter function of Volocity®. Manual and automated counts 150 
gave similar results when compared on non-pigmented samples. The area taken up by regions 151 
of exclusion in each image as a proportion of the total image area was used to standardize the 152 
FoxP3+ cell number per ROI to an equal area of viable tissue between ROIs. 153 
Statistical testing 154 
Statistical analysis was conducted using SPSS software (IBM). A generalized estimating 155 
equation (GEE) with ordinal logistic link function was used to assess association between 156 
Glut1 immunoreactivity score and tumour origins, histotypes and malignancy. Exchangeable 157 
correlation matrix was used to account for repeated measurements from the same tumour 158 
sample. Odds ratio (OR) and its 95% confidence intervals (CI) were reported. Similarly, GEE 159 
with a negative binomial log link function was used to assess the association between Foxp3+ 160 
cell counts and several factors. The factors tested for correlation with FoxP3+ cells count in 161 
tumour samples were: Glut1 immunoreactivity score, whether the tumour was round cell, 162 
epithelial or mesenchymal in origin, and whether the tumour was benign or malignant. In 163 
lymph node samples FoxP3+ cell numbers were correlated with Glut1 immunoreactivity score 164 
and whether the sample was a MLN, TDLN or RLR. The correlation between Glut1 165 
immunoreactivity score and Foxp3+ cell numbers was also assessed within the individual 166 
tumour and lymph node categories. Rate ratio (RR) and its 95% CI were reported. Graphs 167 
were made using R software (R Foundation for Statistical Computing). 168 
Results 169 
Glut1 expression 170 
There was moderate variation in Glut1 labelling between samples (Figures 1a-3a). No 171 
significant difference in Glut1 immunoreactivity was found between different categories of 172 
lymph nodes (Figure 4a ), but malignant tumours had significantly lower expression than 173 
benign ones (Figure 4b, OR=0.160, 95% CI: 0.075-0.343, p<0.001 ). Mesenchymal tumours 174 
had significantly lower Glut1 immunoreactivity than epithelial tumours (OR=0.325, 95% CI: 175 
0.124-0.851, p=0.022 ) although no other significant differences between histotypes could be 176 
observed (Figure 4c). 177 
FoxP3 expression 178 
FoxP3+ cells were identified in all lymph node samples and 73.7% of the tumour samples 179 
(n=42). Their numbers varied greatly both between samples and between different ROIs 180 
within samples (Figures 1b-3b), with the maximum number of FoxP3+ cells in a ROI being 181 
1872 while in some other ROI they were completely absent. The distribution pattern of 182 
FoxP3+ cells also varied between sample types. In round cell tumours they tended to be 183 
scattered throughout the tumour interspersed between the neoplastic cells, while in epithelial 184 
and mesenchymal tumours they were mostly found in the stroma between neoplastic cells or 185 
areas of lymphocytic infiltration, although some had infiltrated between the neoplastic cells 186 
themselves.  187 
Mesenchymal tumours have less FoxP3+ cell infiltration than those of epithelial or round cell 188 
origin 189 
 Samples of mesenchymal origin had significantly fewer FoxP3+ cells per ROI than the 190 
epithelial (RR=0.073, 95% CI: 0.018-0.297, p<0.001) and round cell samples (RR=0.147, 191 
95% CI: 0.041-0.528, p=0.003), although no difference was observed between the other two 192 
histotypes (Figure 5). No difference in FoxP3+ cell prevalence was found between benign 193 
and malignant samples (p=0.094, Figure 6). 194 
Prevalence of FoxP3+ cells correlates with Glut1 expression in tumours in… 195 
Total tumour sample pool 196 
In the overall sample pool ROIs with the higher Glut1 immunoreactivity scores of 2  and 4 197 
had significantly higher FoxP3+ cell counts than those with scores of 0 (respectively 198 
RR=1.912, 95% CI: 1.455-2.513, p<0.001, and RR=1.895, 95% CI: 1.118-2.277, p=0.010) or 199 
1 (respectively RR=2.433, 95% CI: 1.872-3.161 p<0.001, and RR=2.030, 95% CI: 1.448-200 
3.018, p<0.001), although differences could not be demonstrated within these respective pairs 201 
of groups (Figure 7a).  202 
Malignant tumours 203 
When the analysis was conducted on only the malignant tumour samples the same 204 
relationship was shown to be present as in the total tumour sample pool (Figure 7b). 205 
Immunoreactivity scores of 4 were associated with significantly higher FoxP3+ cell counts 206 
than regions scoring 0 (RR=2.565, 95% CI: 1.091-6.032, p=0.031) or 1  (RR=3.367, 95% CI: 207 
1.334-8.499, p=0.010), and ROIs with scores of 2 also had significantly higher FoxP3+ cell 208 
counts than those scoring 0 (RR=2.337, 95% CI: 1.445-3.785, p=0.001) or 1 (RR=3.068, 95% 209 
CI: 1.589-5.930, p=0.001). No differences were found between scores of 2 and 4 or between 210 
0 and 1. Benign samples did not show the same pattern of correlation (Figure 7c). 211 
Round cell tumours 212 
Samples of round cell origin also displayed the same correlation between Glut1 213 
immunoreactivity score and FoxP3+ cell count as the overall tumour sample pool (Figure 7d). 214 
ROIs with scores of 4 had significantly higher FoxP3+ cell counts than those with scores of 0 215 
(RR=3.177, 95% CI: 1.297-7.783, p=0.011) or 1 (RR=5.360, 95% CI: 2.170-13.22, p<0.001), 216 
as did scores of 2 (respectively RR=3.71, 95% CI: 2.121-6.475, p<0.001, and RR=6.253, 217 
95% CI: 2.898-13.49, p<0.001). No differences were found between scores of 2 and 4 or 218 
between 0 and 1. 219 
Mesenchymal tumours 220 
Another correlation between Glut1 immunoreactivity score and FoxP3+ cell count was 221 
found within mesenchymal tumours (Figure 7e). ROIs with immunoreactivity scores of 4 had 222 
significantly higher FoxP3+ cell counts than those with scores of 0 (RR=7.207, 95% CI: 223 
3.353-15.50, p<0.001), 1 (RR=9.300, 95% CI: 4.855-17.80, p<0.001) or 2 (RR=6.184, 95% 224 
CI: 3.17-12.06, p<0.001), and ROIs with scores of 2 had significantly higher FoxP3+ cell 225 
counts than those with scores of 1 (RR=1.502, 95% CI: 1.226-1.842, p<0.001). No other 226 
significant differences between scores was found. 227 
Epithelial tumours 228 
In epithelial tumours (Figure 7f) ROIs with an immunoreactivity score of 2 had 229 
significantly higher FoxP3+ cell counts than those with scores of 1 (RR=1.891, 95% CI: 230 
1.302-2.748, p=0.001). The analysis also reported ROIs with scores of 0 as having higher 231 
counts than those with scores of 1 or 4, but this is thought to be an artefact from a single 232 
anomalous sample. 233 
Lymphoma 234 
 Lymphoma samples also demonstrated a correlation between Glut1 immunoreactivity score 235 
and FoxP3+ cell count (Figure 7g). ROIs with scores of 2 and 4 could not be differentiated, 236 
but they each had significantly higher counts than those with scores of 0 (respectively 237 
RR=4.380, 95% CI: 2.489-7.706, p<0.001, and RR=8.331, 95% CI: 3.702-18.73, p<0.001) 238 
and 1 (respectively RR=9.459, 95% CI: 6.153-14.54, p<0.001; RR=17.975, 95% CI: 8.568-239 
37.713, p<0.001). ROIs with scores of 0 also had significantly higher counts than those 240 
scoring 1 (RR=2.159, 95% CI: 1.642-2.838, p<0.001). 241 
Prevalence of FoxP3+ cells did not differ between lymph node categories 242 
No significant difference was found between the different categories of lymph node 243 
(p=0.085, figure 8). 244 
Prevalence of FoxP3+ cells correlates with Glut1 expression in lymph nodes in… 245 
Total lymph node sample pool 246 
In the overall pool of lymph node samples a higher number of FoxP3+ cells correlated with 247 
a higher Glut1 immunoreactivity score (Figure 9a), with ROIs scoring 4 having significantly 248 
higher counts than those scoring 2 (RR=1.218, 95% CI: 1.033-1.436, p=0.019), and those 249 
scoring 2 having higher counts than those scoring 1 (RR=3.183, 95% CI: 2.678-3.781, 250 
p<0.001).  251 
MLNs 252 
When the analysis was conducted on MLNs (Figure 9b) the same correlation was found as 253 
that in the overall lymph node pool, with ROIs scoring 4 having significantly higher FoxP3+ 254 
cell counts than those scoring 2 (RR=1.343, 95% CI: 1.259-1.763, p=0.034), and ROIs 255 
scoring 2 in turn having significantly higher counts than those scoring 1 (RR=6.666, 95% CI: 256 
6.172-7.199, p<0.001). 257 
RLNs 258 
A weaker correlation was between Glut1 immunoreactivity score and FoxP3+ cell count 259 
was found in RLNs (Figure 9c), with ROIs scoring 4 or 2 having significantly higher counts 260 
than those scoring 1 (respectively RR=3.330, 95% CI: 2.340-4.735, p<0.001, and RR=2.855, 261 
95% CI: 2.125-3.838, p<0.001) 262 
No difference could be found between Glut1 immunoreactivity scores in TDLNs (Figure 263 
9d). 264 
Discussion 265 
This study set out to explore the hypothesis that there is a relationship between the 266 
presence of hypoxia and Tregs in canine tumours and lymph nodes, using Glut1 and FoxP3 as 267 
their respective markers in IHC. Our data demonstrated a positive correlation between Glut1 268 
expression and the prevalence of FoxP3+ cells in both tumours and lymph nodes, which to the 269 
authors’ knowledge is a novel observation in canines. This relationship was present 270 
individually within all three tumour histotypes, as well as specifically within lymphoma cases 271 
and both reactive and metastatic lymph nodes. The finding that there was a positive 272 
correlation within malignant but not benign tumours was most likely because hypoxia is a 273 
less significant determinant of Glut1 expression in benign tumours as they have less 274 
abnormal vasculature (Skinner et al 1995); many factors other than hypoxia are known to 275 
regulate Glut1 expression, such as glucose and insulin levels (Ciaraldi et al 1995), and the 276 
presence of various hormones (Ishida et al 1995, Medina and Owen 2002).  277 
That fewer Tregs were observed in mesenchymal origin tumours may be due to 278 
differences in tissue structure resulting in a reduced ability of Tregs to infiltrate these 279 
tumours. In epithelial tumours Tregs were normally found within the stroma, which appeared 280 
to act as a scaffold to allow them to infiltrate from the vasculature; this facilitation appeared 281 
less commonly in mesenchymal samples.  282 
Benign tumours were observed to have higher Glut1 expression than malignant samples 283 
and epithelial tumours to have higher expression than mesenchymal tumours, thought likely 284 
to reflect factors other than hypoxia. The latter finding is most likely explained by the fact 285 
that epithelial cells generally appeared to express Glut1 more strongly than other cell types 286 
even in normal parts of the tissue, and so higher Glut1 expression in these tissues is unlikely 287 
to indicate higher levels of hypoxia. More likely this indicates a generally higher level of 288 
glucose uptake in epithelial tissues, possibly as a result of greater metabolic demand due to 289 
secretory functions in many cases. This shows that while Glut1 can be indicative of hypoxia, 290 
tissue differences mean the marker is limited for comparisons between tumour types. Since 291 
Glut1 expression has previously been correlated with malignancy our finding to the contrary 292 
is most likely due to the differences in method; previous studies correlated Glut1 with 293 
specific features of malignancy or with long term clinical outcome, whereas the current study 294 
was limited to broader histological classification (Haber et al 1998, Rudlowski et al 2003, 295 
Younes et al 1995). Previous studies also looked at different levels of malignancy within 296 
single types of cancer, whereas we compared a variety of different tumour types. Since, as 297 
mentioned previously, Glut1 expression varies between tissue types our finding that benign 298 
tumours had higher expression is most likely due to the weight of different tumour types in 299 
the sample pool. 300 
As Glut1 is a membrane transport molecule it is unlikely that Tregs are directly attracted 301 
to the molecule itself. Since hypoxia is known to influence Glut1 expression we speculate 302 
that hypoxia is the factor linking these observations, according with a number of studies that 303 
have shown a relationship between Tregs and hypoxia in species other than the dog (Airley et 304 
al 2003, Bussink et al 2003, Clambey et al 2012, Deng et al 2013, Duechler et al 2014, 305 
Facciabene et al 2011, Neildez-Nguyen et al 2015). A hypoxia-mediated increase in Treg 306 
numbers could be attributed to direct stimulation of Treg induction, infiltration or expansion 307 
by HIF, similar to that seen in mucosal inflammatory hypoxia (Clambey et al 2012) or due to 308 
stimulation by other hypoxia-induced molecules in the environment, such as transforming 309 
growth factor β which is synthesised by some hypoxic cells and implicated in Treg 310 
differentiation (Falanga et al 1991, Fu et al 2004). 311 
In contrast to previous studies on both canine and human tumours, our results failed to 312 
detect a correlation between malignancy and numbers of FoxP3+ cells (Kim et al 2012, Oh et 313 
al 2014, Ozgur et al 2014, Wang et al 2015, Yan et al 2011). We also failed to find a 314 
significant difference between the numbers of FoxP3+ cells present in different categories of 315 
lymph nodes, where previous studies had found higher numbers of Tregs in tumour draining 316 
lymph nodes (Nishikawa and Sakaguchi 2010). This could have reflected the diverse range of 317 
tumours in the current study, categorized broadly as benign or malignant, making it less 318 
sensitive in this respect compared to previous studies that have sought to correlate Treg 319 
numbers with particular features of malignancy within specific tumour types, or it could be a 320 
result of differences in measurement due to the use of different techniques.  321 
There were several limitations to this study. FoxP3 can be transiently expressed by non-322 
regulatory T cells so positive expression in cells did not categorically identify them as Tregs 323 
nor did it differentiate the different Treg subclasses (Wang et al 2007); similarly Glut1 324 
expression is influenced by factors other than hypoxia (Ciaraldi et al 1995, Haney 2001, 325 
Sakoda et al 2000). Further research using a greater number of samples of a particular tumour 326 
type and using additional markers would help address these issues; however, despite their 327 
limitations both FoxP3 and Glut1 are commonly used as biomarkers for Tregs and hypoxia 328 
respectively, and FoxP3 in particular is commonly accepted as the best single marker for 329 
Tregs. 330 
The biggest strength of this study was the large number of repeated measurements taken 331 
per sample. By taking measurements at up to 21 locations in each tumour or lymph node it 332 
allowed our analysis to take into account both differences between samples and between 333 
different regions within samples, and allowed a large amount of data to be collected relative 334 
to the number of samples used. 335 
Conclusion 336 
This study revealed a significant relationship between Treg numbers and the levels of 337 
Glut1 expression that we speculate was driven by hypoxia. As far as we are aware this is a 338 
novel finding in dogs, and further research into this relationship is warranted as both hypoxia 339 
and Tregs are thought to be important factors in tumour prognosis and offer potential targets 340 
for novel therapies. A better understanding of their interactions could lead to more effective 341 
treatment protocols in future. 342 
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  524 
Figure legends 525 
Supplemental Figure 1. General pattern of ROI (region of interest) selection. Blue box 526 
indicates tissue section on slide, numbered boxes indicate location of ROIs and the order they 527 
were selected. 528 
 529 
  530 
Supplemental Figures 2-6. Dog, immunohistochemistry for glucose transporter 1 (Glut1), 531 
hematoxylin and eosin. Red highlighting in (b) images indicates regions of strong labelling.  532 
 533 
Supplementary Fig. 2. Dog, immunohistochemistry for glucose transporter 1 (Glut1). Red 534 
highlighting in (b) images indicates regions of strong labelling. Lymphoma, lymph node. 535 
Absence of Glut1 labelling results in an immunoreactivity score of 0. 536 
Supplementary Fig. 3. Dog, immunohistochemistry for glucose transporter 1 (Glut1). (a) 537 
Unaltered images of samples. Red highlighting in (b) images indicates regions of strong 538 
labelling. Adenocarcinoma metastasis, unknown site. Few cells weakly labelling with Glut1 539 
results in a reactivity score of 1. 540 
Supplementary Fig. 4. Dog, immunohistochemistry for glucose transporter 1 (Glut1). (a) 541 
Unaltered images of samples. Red highlighting in (b) images indicates regions of strong 542 
labelling. Cutaneous papilloma. Low percentage of cells labelling for Glut 1, but the majority 543 
of positive cells label strongly, so the region has an immunoreactivity score of 2. 544 
Supplementary Fig. 5. Dog, immunohistochemistry for glucose transporter 1 (Glut1). (a) 545 
Unaltered images of samples. Red highlighting in (b) images indicates regions of strong 546 
labelling. Squamous cell carcinoma metastasis, unknown site. The majority of cells label for 547 
Glut1, but few of these label strongly, yielding an immunoreactivity score of 2. 548 
Supplementary Fig. 6. Dog, immunohistochemistry for glucose transporter 1 (Glut1). (a) 549 
Unaltered images of samples. Red highlighting in (b) images indicates regions of strong 550 
labelling. Anal sac adenocarcinoma. The majority of cells label for Glut1 and the majority of 551 
these label strongly, yielding an immunoreactivity score of 4. 552 
  553 
Supplemental Figure 7a. Malignant melanoma metastasis to mandibular lymph node, 554 
labelled for Forkhead Box P3 (FoxP3). Figure 7b. Regions of exclusion highlighted in green; 555 
FoxP3+ cells counted by Volocity® macro highlighted in contrasting colours. 556 
 557 
 558 
  559 
Figure 1-3. Dog, hematoxylin and eosin. (a) Images labelled by immunohistochemistry for 560 
glucose transporter 1 (Glut1), (b) images labelled for Forkhead Box P3 (Foxp3).  561 
Figure 2. Squamous cell carcinoma, unknown site. Strong Glut1 expression in the nests of 562 
neoplastic cells, particularly towards the periphery. Connective tissue and infiltrating 563 
lymphocytes between nests display lower expression. Most FoxP3+ cells are present in the 564 
connective tissue, with small numbers infiltrating between the neoplastic cells.  565 
Figure 3. Soft tissue sarcoma, unknown site. Uneven labelling of neoplastic cells by Glut1. 566 
Small number of FoxP3+ cells are present infiltrating between the neoplastic cells. 567 
 568 
Figure 4. Proportions of different glucose transporter 1 (Glut1) immunoreactivity scores 569 
compared between (a) different lymph node categories, (b) benign and malignant tumours, (c) 570 
different tumour histotypes. 571 
 572 
 573 
Figure 5-7. Comparisons of the number of FoxP3+ cells per region of interest (ROI) in 574 
tumours. Circles indicate individual ROIs. The median, 25th and 75th percentiles are indicated 575 
by the box, and the whiskers indicate the highest and lowest values within 1.5 times the 576 
length of the quartiles. Letters group results that were not significantly different, where 577 
results do not share a letter a statistically significant difference (p<0.05) was present. Figure 578 
5. Comparison between different tumour histotypes. Figure 6. Comparison between benign 579 
and malignant tumours. Figure 7. Comparisons between different glucose transporter 1 580 
(Glut1) immunoreactivity in different categories of tumours. Figure 7a.  All tumour samples. 581 
Figure 7b. Malignant samples. Figure 7c. Benign samples. Figure 7d. Samples of round cell 582 
origin. Figure 7e. Mesenchymal cell origin. Figure 7f. Epithelial cell origin. Figure 7g. 583 
Lymphoma samples.  584 
Figures 8 and 9. Comparisons of the number of FoxP3+ cells per region of interest (ROI) in 585 
lymph nodes. Circles indicate individual ROIs. The median, 25th and 75th percentiles are 586 
indicated by the box, and the whiskers indicate the highest and lowest values within 1.5 times 587 
the length of the quartiles. Letters group results that were not significantly different, where 588 
results do not share a letter a statistically significant difference (p<0.05) was present. Figure 589 
8. Comparison between lymph node categories. Figure 9. Comparison between Glut1 590 
immunoreactivity scores in different lymph node categories Figure 9a. All lymph node 591 
samples. Figure 9b. Metastatic lymph nodes. Figure 9c. Reactive lymph nodes. Figure 9d. 592 
Tumour draining lymph nodes. 593 
 594 
Supplementary Table 1. Antibodies used for immunohistochemistry with their respective 595 
controls and concentrations 596 
 597 
Supplementary Table 1. Antibodies used for immunohistochemistry with their respective controls and 
concentrations 
Antibody Supplier Product 
code/clone 
number 
Raised 
in 
Positive 
control 
tissue 
Negative 
control 
Secondary 
antibody 
Concentration 
Polyclonal 
anti-canine 
glucose 
transporter 
1 antibody 
Abcam ab15309 Rabbit Healthy 
kidney 
Normal 
rabbit IgG 
(Vector Labs 
I-1000) 
Envision 
HRP® 
(Dako 
K4002) 
2µg/ml 
Monoclona
l anti-
canine 
FoxP3 
Ebioscienc
e 
14-4321-
85 / eBR2a 
Rat Reactive 
lymph 
node 
Rat Ig 
isotype 
control 
(eBioscienc
e 14-4321-
85, clone 
eBR2a) 
ImmPRES
S HRP 
Anti-Rat 
Ig® (Vector 
Labs MP-
7404) 
5µg/ml 
